Clinical trial
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
NCT03417882
Study timeline
Study start (actual)2019-01-03Date precision: day
Registry last updated2023-08-08
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic NSCLCunresolved
Interventions
GRN-1201 + PembrolizumabBIOLOGICAL
Sponsors & collaborators
BrightPath Biotherapeuticslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03417882 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.